Loading viewer...
investor_presentation
Format: PDF investor_presentation
Nuvation Bio is a late clinical-stage oncology company developing next-generation cancer therapeutics, including taletrectinib, a potentially best-in-class ROS1 inhibitor completing pivotal trials, and safusidenib, a brain-penetrant mIDH1 inhibitor in Phase 2 development. With a robust cash balance of $577 million, the company targets becoming a commercial-stage organization in 2025.
investor_presentation
37 Pages
investor_presentation
4 Pages
Alder Biopharmaceuticals
Oportun Financial Corporation Investor Presentation 2020
investor_presentationinvestor_presentation
43 Pages
Oportun Financial Corporation